{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:15:42Z","timestamp":1765545342759,"version":"build-2065373602"},"reference-count":31,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T00:00:00Z","timestamp":1326672000000},"content-version":"vor","delay-in-days":2359,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:p>\n                    <jats:bold>Study Objective<\/jats:bold>\n                    . To determine the frequency of monitoring of international normalized ratio (INR) within 14 days of coprescription of warfarin and antimicrobial therapy and to evaluate differences in INR monitoring among antimicrobials.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design<\/jats:bold>\n                    . Retrospective cohort study.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Setting<\/jats:bold>\n                    . Group model health maintenance organization.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Subjects<\/jats:bold>\n                    . Patients aged 65 years or older who were taking warfarin and an antimicrobial agent.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Measurements and Main Results<\/jats:bold>\n                    . Patients who received dispensings of both warfarin and an antimicrobial agent were identified. We found 2959 coprescribing instances in 1816 patients. The INR values were obtained for 2267 (77%) coprescribing situations within 14 days. Monitoring occurred more frequently (p&lt;0.001) when warfarin was coprescribed with fluoroquinolones (641 [85%] of 755 situations), metronidazole (59 [81%] of 73), tetracyclines (274 [80%] of 341), or macrolides (201 [83%] of 243) than when warfarin was coprescribed with sulfonamides (35 [66%] of 53), penicillins (604 [71%] of 856), or cephalosporins (419 [71%] of 591). Among monitored patients, a higher proportion of monitoring (p&lt;0.001) occurred within 7 days for patients prescribed antifungals (87%), fluoroquinolones (88%), tetracyclines (82%), metronidazole (86%), sulfonamides (86%), or macrolides (85%) than for patients prescribed cephalosporins (68%) or penicillins (75%).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion<\/jats:bold>\n                    . Most older patients coprescribed warfarin and an antimicrobial in our organization had INR monitoring within 7 days. This is consistent with appropriate practice to manage a risk of clinically important drug\u2010drug interaction between an antimicrobial agent and warfarin. Prospective identification of patients requiring INR monitoring after coprescription of interacting drugs by using merged administrative pharmacy and laboratory data should be further evaluated as a tool to improve clinical outcomes.\n                  <\/jats:p>","DOI":"10.1592\/phco.2005.25.8.1055","type":"journal-article","created":{"date-parts":[[2005,10,10]],"date-time":"2005-10-10T04:47:51Z","timestamp":1128919671000},"page":"1055-1061","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Warfarin Monitoring in Ambulatory Older Individuals Receiving Antimicrobial Therapy"],"prefix":"10.1002","volume":"25","author":[{"given":"Marsha A.","family":"Raebel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Witt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikki M.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Magid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,16]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"337","volume-title":"Pharmacotherapy, a pathophysiologic approach","author":"Haines ST","year":"2002"},{"volume-title":"Warfarin. Drug\u2010Reax. Interactive drug interactions. Micromedex Healthcare Series","year":"2004","key":"e_1_2_1_3_2"},{"key":"e_1_2_1_4_2","first-page":"1177","article-title":"Possible potentiation of warfarin by fluconazole","volume":"24","author":"Seaton TL","year":"1990","journal-title":"Drug Intell Clin Pharm"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.Supplement_3.S327"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0090-9556(25)07369-6","article-title":"Warfarin\u2010fluconazole. II. A metabolically based drug interaction: in vivo studies","volume":"24","author":"Black DJ","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1993.tb04316.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(200001)63:1<28::AID-AJH6>3.0.CO;2-J"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019048-199909000-00014"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(80)90568-3"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198001033020106"},{"key":"e_1_2_1_12_2","first-page":"1155","article-title":"Drug interaction between co\u2010trimoxazole and warfarin [letter]","volume":"36","author":"Greenlaw CW.","year":"1979","journal-title":"Am J Hosp Pharm"},{"key":"e_1_2_1_13_2","first-page":"1399","article-title":"Co\u2010trimoxazole and warfarin: a case report of an interaction","volume":"35","author":"Errick JK","year":"1978","journal-title":"Am J Hosp Pharm"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.53.621.388"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198325060-00004"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-198508000-00037"},{"key":"e_1_2_1_17_2","first-page":"210","article-title":"Effect of erythromycin in patients receiving long\u2010term warfarin therapy","volume":"8","author":"Weibert RT","year":"1989","journal-title":"Clin Pharm"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1984.00350220145031"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-198301000-00026"},{"volume-title":"Diflucan (fluconazole) product information","year":"1999","author":"Roerig Division of Pfizer, Inc.","key":"e_1_2_1_20_2"},{"volume-title":"Cipro XR (ciprofloxacin extended\u2010release tablets) product information","year":"2003","author":"Bayer Pharmaceutical Corporation.","key":"e_1_2_1_21_2"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199914040-00005"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1991.tb00358.x"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(89)80689-8"},{"key":"e_1_2_1_25_2","first-page":"970","article-title":"The risk and severity of bleeding complications in elderly patients treated with warfarin","volume":"124","author":"Fihn SD","year":"1996","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04110.x"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912700222011175"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-11-901"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.6.600.34735"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-8_Part_2-200110161-00009"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/1467-9868.00346"},{"key":"e_1_2_1_32_2","first-page":"34","article-title":"Clinical pharmacy anticoagulation services in a group model health maintenance organization","volume":"18","author":"Witt DM","year":"1998","journal-title":"Pharm Pract Manag Q"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.2005.25.8.1055","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.2005.25.8.1055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:15:19Z","timestamp":1761066919000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.2005.25.8.1055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1592\/phco.2005.25.8.1055"],"URL":"https:\/\/doi.org\/10.1592\/phco.2005.25.8.1055","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2005,8]]},"assertion":[{"value":"2012-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}